William Wu, MD
Cardiovascular Disease · San Antonio, TXNPI 1346246626
Payments from drug & device makers
Across 352 payments — averaging $204.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$67K
- Novo Nordisk$567
- E.r. Squibb & Sons, L.L.C.$550
- Abbott$386
- Esperion Therapeutics, Inc.$304
- Lilly USA, LLC$296
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,4838%
- Education$100%
- Other$66,58392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 51 | $66,970 |
| Novo Nordisk | 51 | $567 |
| E.r. Squibb & Sons, L.L.C. | 59 | $550 |
| Abbott | 14 | $386 |
| Esperion Therapeutics, Inc. | 12 | $304 |
| Lilly USA, LLC | 17 | $296 |
| Johnson & Johnson | 21 | $276 |
| AstraZeneca | 6 | $256 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $253 |
| Amgen | 11 | $219 |
| Pfizer | 22 | $201 |
| Boehringer Ingelheim | 10 | $193 |
| Medtronic | 2 | $177 |
| Abiomed | 1 | $150 |
| Scpharmaceuticals Inc. | 7 | $135 |
| Merck | 8 | $132 |
| AbbVie | 2 | $125 |
| Novartis | 6 | $114 |
| Irhythm Technologies, Inc. | 2 | $102 |
| Biotronik Inc. | 4 | $102 |
| Boston Scientific | 4 | $93 |
| Lexicon Pharmaceuticals, Inc. | 4 | $80 |
| GSK | 3 | $54 |
| Acist Medical Systems, Inc. | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Bayer | 1 | $26 |
| Teleflex LLC | 1 | $26 |
| Reflow Medical Inc | 1 | $24 |
| Philips North America LLC | 2 | $24 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Medicomp Inc | 1 | $19 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 2 | $15 |
| Cvrx, Inc. | 2 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Cashflow Solutions, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$66,583
- Legacy$150
- CoreValve Evolut$144
- NEXLIZET$125
- NEXLETOL$125
- FARXIGA$124
- CAMZYOS$116
How this compares
$72,076 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 521 | $565,685 |
| EliquisApixaban | 493 | $427,452 |
| MounjaroTirzepatide | 213 | $243,658 |
| EntrestoSacubitril/Valsartan | 285 | $232,553 |
| XareltoRivaroxaban | 166 | $137,036 |
| Repatha SureclickEvolocumab | 133 | $110,078 |
| FarxigaDapagliflozin Propanediol | 72 | $59,620 |
| Ranolazine ErRanolazine | 392 | $33,403 |
| BrilintaTicagrelor | 46 | $29,759 |
| VerquvoVericiguat | 30 | $26,843 |
| NexletolBempedoic Acid | 40 | $25,741 |
| Repatha SyringeEvolocumab | 24 | $18,014 |
| JardianceEmpagliflozin | 14 | $17,130 |
| Praluent PenAlirocumab | 15 | $9,952 |
| ClopidogrelClopidogrel Bisulfate | 915 | $9,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $567 | $565,685521 claims |
| PfizerEliquis | $201 | $427,452493 claims |
| Lilly USA, LLCMounjaro | $296 | $243,658213 claims |
| NovartisEntresto | $114 | $232,553285 claims |
| Johnson & JohnsonXarelto | $276 | $137,036166 claims |
| AstraZenecaFarxiga, Brilinta | $256 | $89,379118 claims |
| MerckVerquvo | $132 | $26,84330 claims |
| Esperion Therapeutics, Inc.Nexletol | $304 | $25,74140 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $193 | $23,25427 claims |
| GSKBreo Ellipta | $54 | $5,49514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in San Antonio
- Chandrasekhar KunavarapuSan Antonio$765K
- Robert SchnitzlerSan Antonio$425K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.